Long-term changes in circulating CD4 T lymphocytes in virologically suppressed patients after 6 years of highly active antiretroviral therapy

作者
Kimberly Y. Smith,Evgenia Aga,Ronald J. Bosch,Hernán Valdez,Elizabeth Connick,ALAN L. LANDAY,Daniel R. Kuritzkes,Barry H. Gross,Isaac R. Francis,J M McCune,Harold A. Kessler,Michael M. Lederman
出处
期刊:AIDS [Lippincott Williams & Wilkins]
卷期号:18 (14): 1953-1956 被引量:41
标识
DOI:10.1097/00002030-200409240-00012
摘要

Highly active antiretroviral therapy (HAART) initiated in advanced HIV disease is associated with CD4 lymphocyte increases (200–300 cells/mm3after 2–4 years), although longer-term cellular dynamics have not been studied. We observed a significant median CD4 lymphocyte increase of 126 cells/mm3and 54 naive CD4 lymphocytes from year 3 to 6 of HAART among 20 individuals with pre-HAART CD4 cell counts of 100–300 cells/mm3. This cohort represents the longest prospective immunological follow-up of virologically suppressed patients on HAART. Untreated HIV infection leads to a progressive loss of peripheral CD4 lymphocytes, immunological impairment and an increased risk of opportunistic illnesses. Several studies have examined CD4 cell responses to potent antiretroviral therapy, and have demonstrated that prolonged successful viral suppression is associated with substantial increases in CD4 lymphocyte counts and clinical benefit [1]. After 2–4 years of antiretroviral therapy, mean (or median) CD4 increases are approximately 200–300 cells/mm3 [2–5]. However, the rate of the CD4 cell increase has been shown to diminish over time with little additional increase observed after 3–4 years of therapy [2–5]. AIDS Clinical Trials Group (ACTG) 315 was a study designed to evaluate the immunological effect of highly active antiretroviral therapy (HAART). HIV-infected individuals with CD4 cell counts between 100 and 300 cells/mm3 and a history of therapy with zidovudine for at least 3 months were enrolled in this three-center study. Patients with previous treatment with lamivudine or any HIV-1 protease inhibitor were excluded. After treatment with zidovudine, lamivudine and ritonavir for a minimum of 48 weeks, study participants rolled over into ACTG 375, in which changes in antiretroviral treatment could be made if plasma HIV-1-RNA levels were more than 100 copies/ml, and changes were required if plasma HIV-1-RNA levels were repeatedly more than 3000 copies/ml. Twenty patients with plasma HIV-1-RNA levels less than 1000 copies/ml at 3 years and for at least 75% of the determinations between week 12 and year 3 have been described in detail through 3 years of follow-up [4]. The same 20 patients continued in follow-up, and CD4 and CD8 lymphocyte counts and subsets are available through 6 years of HAART. Measurements were averaged within a window from week 266 to week 322 (one subject went off-study at 4.5 years, and this timepoint was carried forward in all the following analyses). None of the subjects had confirmed HIV-1-RNA levels greater than 1000 copies/ml between years 3 and 6. At year 6, 17 subjects remained on zidovudine, lamivudine and ritonavir, one subject was on zidovudine, lamivudine and indinavir, one subject was on zidovudine, lamivudine, ritonavir and saquinavir, and one subject was on stavudine, nevirapine, ritonavir and saquinavir. No subjects took IL-2 or other adjunctive immune therapies. Changes in lymphocyte subsets are presented as medians and are summarized in Fig. 1. The Wilcoxon signed-rank test was used to evaluate whether median changes from year 3 to year 6 were different from zero, and the Wilcoxon rank-sum test compared changes between subjects above versus below the median thymus thickness. There were no corrections for multiple comparisons. CD4 cell counts continued to increase from year 3 to year 6, and the median increase of 126 cells/mm3 was statistically significant (P < 0.001, 42 cells/mm3 per year). From baseline to year 3, CD4 cell counts increased an average of 71 cells/mm3 per year [4]. Notably, the median change in CD4 cell count from baseline to year 1 was +159, whereas the average yearly change from year 3 to year 6 was +42 cells/mm3. Surprisingly, 55% of subjects demonstrated decreases in CD4 cell counts (ranging from −20 to −178 cells) from year 5 to year 6. During the study period, no subject had a confirmed CD4 cell count above 900 cells/mm3; one subject had a confirmed CD4 cell count above 800 cells/mm3 and six subjects had confirmed CD4 cell counts above 700 cells/mm3.Fig. 1. Median CD4 and CD8 lymphocyte counts and subsets over time (top two panels) and median CD4 and CD8 activation percentages over time (bottom panel).: Each timepoint represents 20 subjects.The number of peripheral blood memory (CD45RO+/CD45RA−) CD4 lymphocytes increased significantly from baseline (127 cells/mm3) to year 3 (241 cells/mm3) and to year 6 (321 cells/mm3) (P < 0.001). In addition, the number of naive (CD45RA/62L) CD4 and CD8 T lymphocytes increased significantly (P < 0.001); the median year 3 to year 6 increases were 54 and 113 cells/mm3, respectively (Fig. 1). Unexpectedly, the percentages of activated (CD38/HLA-DR) CD4 and CD8 lymphocytes increased from year 3 to year 6, in contrast to the declines observed from baseline to year 3 (Fig. 1). This pattern was observed in the majority of subjects; 75 and 85% of subjects increased activated CD4 and CD8 cell percentages over this period, respectively. The thymus size was measured approximately one year after the initiation of antiretroviral therapy in 16 of the subjects in this study using methods described elsewhere [6]. We have previously described a correlation between thymus size as measured by chest computed tomography scan and the number and percentage of naive CD4 cells in these subjects after one year of antiretroviral therapy [7]. Comparing naive CD4 cell increases from baseline to year 6 among the seven subjects with year one thymus size (thickness) above the median (5 mm) to the nine at or below the median, a marginally significant difference was noted (median 204 versus 97 naive cells/mm3, P = 0.071, Wilcoxon test). No differences were seen in total CD4 cell increases (319 versus 306 cells/mm3). This cohort represents the longest prospective immunological follow-up of virologically suppressed patients on potent antiretroviral therapy. We have demonstrated sustained CD4 cell increases in subjects who had moderately advanced HIV disease at the start of therapy. It is notable, however, that despite improvements in absolute, naive and memory CD4 cell counts and percentages, the majority of subjects have CD4 cell subsets that are lower than seen among HIV-negative subjects. We have expanded upon our previous findings, and confirmed the findings of others regarding the importance of thymus size in naive CD4 cell restoration after HAART [8,9]. In addition, we have demonstrated that despite long-term viral suppression for more than 5 years, subjects have persistently elevated markers of immune activation, and the majority of subjects demonstrated small increases in immune activation in the final 3 years of treatment. The mechanism for this is unclear. It is possible that the increase in CD4 cells has provided new targets for viral replication. Low-level increases in viral replication or early viral escape could thus be driving heightened immune activation. We could not find a correlation between plasma HIV RNA and immune activation in these subjects; however, as most subjects had HIV levels below the level of detection of the assay used in this study, a more sensitive measure of viral replication may be needed to answer this question. We will address this and other questions in the follow-up study to ACTG 375, ACTG 5136, which will examine the effect of HAART intensification in these subjects. Sponsorship: This work was supported by the AIDS Clinical Trials Group and by grants AI 38855, AI 38858 and AI 25879 from the National Institutes of Health and by GCRC grant RR-0051 and Cancer Center grant CA-46934 at the University of Colorado Health Sciences Center. HIV-RNA testing was performed by Glaxo-Wellcome Inc., who also supplied zidovudine and lamivudine; Abbott Laboratories supplied ritonavir; Bristol–Myers Squibb supplied stavudine and didanosine; Hoffman La Roche supplied saquinavir; and Agouron Pharmaceuticals supplied delavirdine.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lulu完成签到,获得积分10
1秒前
Bai发布了新的文献求助10
1秒前
Akim的应助被blinkals57采纳,获得10
1秒前
ui24发布了新的文献求助10
1秒前
1秒前
淡定访琴完成签到,获得积分10
2秒前
搜集达人的应助被mhx1234567890采纳,获得10
3秒前
5秒前
孤独的凤完成签到,获得积分10
5秒前
6秒前
6秒前
音阙发布了新的文献求助10
6秒前
Sxya发布了新的文献求助30
7秒前
dingyushu完成签到,获得积分10
7秒前
秋风的应助被pinkstar采纳,获得10
7秒前
科研通AI6.3的应助被向星采纳,获得10
8秒前
8秒前
8秒前
dkfsgeicn完成签到,获得积分10
9秒前
情怀的应助被ZYH采纳,获得10
9秒前
10秒前
orixero的应助被Kevin采纳,获得10
10秒前
phoebe发布了新的文献求助10
11秒前
研友_VZG7GZ的应助被香辣牛排采纳,获得10
11秒前
11秒前
12秒前
2dingyushu完成签到,获得积分10
12秒前
852的应助被甜蜜的电灯胆采纳,获得10
12秒前
科研通AI6.3的应助被晚风采纳,获得10
12秒前
melon发布了新的文献求助20
12秒前
疯狂加载ing的应助被hin采纳,获得10
13秒前
wangbw发布了新的文献求助10
14秒前
缺口口发布了新的文献求助80
15秒前
leyi发布了新的文献求助10
15秒前
15秒前
six发布了新的文献求助10
15秒前
16秒前
9dingyushu完成签到,获得积分10
16秒前
16秒前
深情安青的应助被LuoYR@SZU采纳,获得10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178807
求助须知:如何正确求助?哪些是违规求助? 9569558
关于积分的说明 21805222
捐赠科研通 7773974
什么是DOI,文献DOI怎么找? 3432933
关于科研通互助平台的介绍 2556873
邀请新用户注册赠送积分活动 2478593